You are here

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Cypress, California, 90630 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects diagnosed with a fever secondary to an uncomplicated acute viral or bacterial
infection.

- Oral temperature measurement from 100 to 104 degrees Fahrenheit.

- Onset of fever 3 days or less.

- Otherwise good health.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Fever secondary to a chronic underlying medical condition or serious infection.

- Currently taking antibiotics or antivirals.

- Currently taking any medication which may interfere with the assessment of fever.

- Pregnancy or breast-feeding.

- Any serious medical or psychiatric disorder.

NCT01035346
Pfizer
Terminated
Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now